InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.70
(
-0.11%
)
Bitcoin
64,947.24
(
-0.29%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 511
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: biomaven0 post# 143859

Thursday, 06/14/2012 10:54:15 AM

Thursday, June 14, 2012 10:54:15 AM

Post# of 252255

not aware of any examples of this (coformulation)



I think it happens all the time and I don't see why FTC would get involved. Will FTC get involved when GILD coformulates GS-7977 which they acquired via Pharmasset with their own in-house NS5a?

If ABT got away with coformulating lopinavir and ritonavir and then raising the price of stand-alone ritonavir five-fold to drive the PI business toward Kaletra, I think Roche has little to worry about here.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up